Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy

Ítems similars

• Plasma Eicosanoid Levels in Tuberculosis and Tuberculosis-Diabetes Co-morbidity Are Associated With Lung Pathology and Bacterial Burden
  per: Pavan Kumar, Nathella, et al.
  Publicat: (2019)
• Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis – Diabetes co-morbidity
  per: Kumar, Nathella Pavan, et al.
  Publicat: (2021)
• Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment
  per: Kumar, Nathella P., et al.
  Publicat: (2018)
• Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co‐morbidity
  per: Kumar, Nathella P., et al.
  Publicat: (2018)
• Modulation of dendritic cell and monocyte subsets in tuberculosis-diabetes co-morbidity upon standard tuberculosis treatment
  per: Kumar, Nathella Pavan, et al.
  Publicat: (2016)